Astragaloside IV exerts antiviral effects against coxsackievirus B3 by upregulating interferon-γ

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 2, 2006, Pages 190-195

  Zhang, Yuanyuan ^a   Zhu, Haiyan ^a   Huang, Chenggang ^a   Cui, Xiaolan ^b   Gao, Yingjie ^b   Huang, Yang ^b   Gong, Wenfeng ^b   Zhao, Ye ^b   Guo, Shanshan ^b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Astragaloside IV; Coxsackievirus B3; IFN ; Viral myocarditis

Indexed keywords

ASTRAGALOSIDE IV; ASTRAGALUS EXTRACT; GAMMA INTERFERON; GUANIDINE; MESSENGER RNA; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; ASTRAGALOSIDE A; SAPONIN; TRITERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; ASTRAGALUS PLANT; CELL DEATH; CELL INFILTRATION; CONTROLLED STUDY; COXSACKIE VIRUS B3; HEART MUSCLE CELL; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; MALE; MONONUCLEAR CELL; MORBIDITY; MORTALITY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; VIRUS TITRATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; COXSACKIE VIRUS INFECTION; DRUG EFFECT; ENTEROVIRUS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MYOCARDITIS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UPREGULATION; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANIMALS, NEWBORN; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELLS, CULTURED; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; INJECTIONS, INTRAPERITONEAL; INTERFERON TYPE II; MALE; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; MYOCARDITIS; MYOCYTES, CARDIAC; RNA, MESSENGER; SAPONINS; TRITERPENES; UP-REGULATION; VIRUS REPLICATION;

EID: 33746423609     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000199683.43448.64     Document Type: Article

References (28)

1. Maier R, Krebs P, Ludewig B. Immunopathological basis of virus-induced myocarditis. Clin Dev Immunol. 2004;1:1-5.
2. Tschope C, Westermann D, Steendijk P, et al. Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis: effects of carvedilol and metoprolol. Eur J Pharmacol. 2004;491:173-179.
3. Galabru J, Hovanessian A. Autophosphorylation of the protein kinase dependent on double stranded RNA. J Biol Chem. 1987;262:15538-15544.
4. Stewart MJ, Blum MA, Sherry B. PKR's protective role in viral myocarditis. Virology. 2003;314:92-100.
5. Hunziker IP, Harkins S, Feuer R, et al. Generation and analysis of an RNA vaccine that protects against coxsackievirus B3 challenge. Virology. 2004;330:196-208.
6. Kim JY, Jeon ES, Lim BK, et al. Immunogenicity of a DNA vaccine for Coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge. Vaccine. 2005;23:1672-1679.
7. Xu W, Shen Y, Jiang Z, et al. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine. 2004;22:3603-3612.
8. Wang YP, Li XY, Song CQ, et al. Effect of astragaloside IV on T, B lymphocyte proliferation and peritoneal macrophage function in mice. Acta Pharmacol Sin. 2002;3:263-266.
9. Yang YZ, Jin PY, Guo Q, et al. Effect of Astragulas membranaceus on natural killer cell activity and induction of α- and γ-interferon in patients with Coxsackie B viral myocarditis. Chin Med J. 1990;103:304-307.
10. Yang YZ, Jin PY, Guo Q, et al. Treatment of experimental Coxsackie B3 viral myocarditis with Astragalus membranaceus in mice. Chin Med J. 1990;103:14-18.
11. Li ZP, Cao Q. Effects of astragaloside IV on myocardial calcium transport and cardiac function in ischemic rats. Acta Pharmacol Sin. 2002;10:898-904.
12. Xia Q, Ma Q, Shi JA, et al. Chemical analysis of Astragali (Huangqi) in China: a comparison with its adulterants and seasonal variations. J Agric Food Chem. 2002;50:4861-4866.
13. Yuan W, Chen H, Yang Y, et al. Effect of Astragalus membranaceus electric activities of cultured rat beating heart cells infected with CVB3. Chin Med J. 1990;3:177-182.
14. Bishop JM, Koch G. Plaque assay for poliovirus and poliovirus specific RNAs. In: Habel K, Salzman NP (eds). Fundamental Techniques in Virology. Academic Press: New York; 1969: 131-145.
15. Wang A, Cheung KM, Zhang H, et al. Specific inhibition of Coxsackievirus B3 translation and replication by phosphorothioate antisense oligodeoxynucleotides. Antimicrob Agents Chemother. 2001;4:1043-1052.
16. Muckelbauer JK, Kremer M, Minor I, et al. The structure of Coxsackievirus B3 at 3.5 A resolution. Structure. 1995;7:653-667.
17. Luo YM, Qin Z, Hong Z, et al. Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia. Neurosci Lett. 2004;363:218-223.
18. Crowell RL. Specific cell-surface alteration by enteroviruses as reflected by viral attachment interference. J Bacteriol. 1966;91:198-204.
19. Bergelson JM, Mohanty JG, Crowell RL, et al. Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J Virol. 1995;69:1903-1906.
20. Badorff C, Lee GH, Lamphear BJ. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999;5:320-326.
21. Chow LH, Beisel KW, McManus BM. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viralpathogenesis of myocardial injury. Lab Invest. 1992;66:24-31.
22. Mason JW. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res. 2003;60:5-10.
23. Maisch B, Ristic AD, Hufnagel G. Pathophysiology of viral myocarditis: the role of the humoral immune response. Cardiovasc Pathol. 2002;11:112-122.
24. Daliento L, Calabrese F, Tona F, et al. Successful treatment of enterovirus-induced myocarditis with interferon-γ. J Heart Lung Transplant. 2003;22:214-217.
25. Kuhl U, Pauschinger M, Schwimmbeck P, et al. Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107:2793-2798.
26. Billiau A. Interferon-gamma: biology and role in pathogenesis. Adv Immunol. 1996;62:61-130.
27. Henke A, Zell R, Martin U, et al. Direct interferon-γ-mediated protection caused by a recombinant coxsackievirus B3. Virology. 2003;315:335-344.
28. Karupiah G, Xie QW, Buller RM, et al. Inhibition of viral replication by interferon-gamma induced nitric oxide synthase. Science. 1993;261:1445-1448.